Amgen
Amgen is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
Sponsor Universitaetsklinikum Schleswig-Holstein AöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
HOVON 146 ALL: Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. A phase II trial.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Amgen?
The 2026-10-09 snapshot links Amgen to 9 distinct CTIS trials. Recorded services include Contact on product labeling for information regarding product, trial, emergency unblinding, Medicinal product management, Contact on product labelling, for information, Contact on product labelling, for information regarding product, trial, emergency unblinding, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Amgen?
The most frequently recorded therapeutic areas are Haematological Malignancies, Gastroenterology, Solid Tumor Oncology. Recorded phases include Phase 3, Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Amgen conducted?
The linked trials record locations in 24 countries, including Czechia, Italy, Austria, Belgium, Spain. These are trial locations, not confirmed office locations or countries where Amgen delivered services.
What can this page tell me about Amgen's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Amgen. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Amgen GmbH
- Amgen Inc.
- Amgen Limited